Mirum Pharmaceuticals, Inc. provided sales guidance for the year 2024. The company expects net product sales to be $310 million to $320 million for 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.94 USD | +0.73% | -5.08% | -15.14% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.14% | 1.17B | |
+27.17% | 44.96B | |
+0.00% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.08% | 26.08B | |
-21.09% | 19.03B | |
+6.40% | 12.75B | |
+28.79% | 12.06B | |
-4.19% | 11.75B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024